ライフサイエンスコーパス: extracorporeal membrane oxygenation

1 required temporary circulatory support (with extracorporeal membrane oxygenation).

2 1.5%) died (13.0 deaths/1,000 person-days of extracorporeal membrane oxygenation).

3 fected (50.4 infections/1,000 person-days of extracorporeal membrane oxygenation).

4 versus 80.7% (79.8-81.6) from donors without extracorporeal membrane oxygenation.

5 ualized at each PEEP level in 15 patients on extracorporeal membrane oxygenation.

6 respiratory failure supported by venovenous extracorporeal membrane oxygenation.

7 lar blockade, prone position ventilation, or extracorporeal membrane oxygenation.

8 crease until day 4-5 after the initiation of extracorporeal membrane oxygenation.

9 d with an increased mortality in veno-venous extracorporeal membrane oxygenation.

10 Percutaneous extracorporeal membrane oxygenation.

11 severe medical conditions than those without extracorporeal membrane oxygenation.

12 arge disposition, tracheostomy, and need for extracorporeal membrane oxygenation.

13 ntravascular hemolysis occurs in patients on extracorporeal membrane oxygenation.

14 proved the safety and ease of application of extracorporeal membrane oxygenation.

15 demHeart; and new devices for institution of extracorporeal membrane oxygenation.

16 normal neuroimaging findings during or after extracorporeal membrane oxygenation.

17 g electrophysiology study/ablation, while on extracorporeal membrane oxygenation.

18 ar ejection while on peripheral venoarterial extracorporeal membrane oxygenation.

19 lant survival and superior to survival after extracorporeal membrane oxygenation.

20 enal, and liver insults) than donors without extracorporeal membrane oxygenation.

21 tients diagnosed in France, of whom 161 with extracorporeal membrane oxygenation.

22 ere successfully transplanted from donors on extracorporeal membrane oxygenation.

23 oxygenation and mortality for veno-arterial extracorporeal membrane oxygenation.

24 t on outcome of nosocomial infections during extracorporeal membrane oxygenation.

25 derwent urgent surgery, including two during extracorporeal membrane oxygenation.

26 0.01), intubation (58% vs. 8.3%; p < 0.01), extracorporeal membrane oxygenation (17.9% vs. 1.7%, p <

27 ac disease duration greater than 2 years pre-extracorporeal membrane oxygenation (2.8 [1.2-6.9]), and

28 between patients managed with versus without extracorporeal membrane oxygenation (22% vs 30%) (p = 0.

29 0.5] vs. 16.5 [9-25.5] days; p < 0.001), and extracorporeal membrane oxygenation (25.5 [10.75-54] vs.

30 73.0%; p < 0.001), oxygen rescue therapies (extracorporeal membrane oxygenation 5.8% vs 0.9%; p = 0.

31 ed sixty-five patients underwent veno-venous extracorporeal membrane oxygenation, 775 patients underw

32 core II 37 [32-47]) who underwent peripheral extracorporeal membrane oxygenation (87% veno-venous) fo

33 d function between recipients from donors on extracorporeal membrane oxygenation (92.7% [85.9-96.3%])

34 and matching recipients from donors without extracorporeal membrane oxygenation (95.4% [93.0-97.0%])

35 ac arrest, cardiopulmonary resuscitation, or extracorporeal membrane oxygenation (adverse events) exp

36 ients (86%) could be weaned off venoarterial extracorporeal membrane oxygenation after 5.5 days (2-12

37 of thrombocytopenia in patients supported by extracorporeal membrane oxygenation after cardiac surger

38 Extracorporeal membrane oxygenation, an accepted rescue

39 Among these patients, 64 donors on extracorporeal membrane oxygenation and 10,805 donors wi

40 Extracorporeal membrane oxygenation and adrenalectomy sh

41 deficits in school-age survivors of neonatal extracorporeal membrane oxygenation and congenital diaph

42 ere acute lung failure receiving veno-venous extracorporeal membrane oxygenation and explore risk fac

43 In a multivariate model evaluating pre-extracorporeal membrane oxygenation and extracorporeal m

44 ssociations between survival and various pre-extracorporeal membrane oxygenation and extracorporeal m

45 Univariate analysis identified pre-extracorporeal membrane oxygenation and extracorporeal m

46 atric patients aged 0-18 were supported with extracorporeal membrane oxygenation and had an indicatio

47 Median duration of extracorporeal membrane oxygenation and ICU stay were 10

48 2 adult patients supported with venoarterial extracorporeal membrane oxygenation and included in the

49 The patient was slowly rewarmed with extracorporeal membrane oxygenation and made an exceptio

50 n in spite of treatment with venous-arterial extracorporeal membrane oxygenation and mechanical circu

51 ve clinical improvement allowed weaning from extracorporeal membrane oxygenation and removal of the p

52 scribe donors after brain death with ongoing extracorporeal membrane oxygenation and to analyze the o

53 t school-age (8-12 yr) survivors of neonatal extracorporeal membrane oxygenation and/or congenital di

54 ein C), novel therapeutic ideas (statins and extracorporeal membrane oxygenation), and solidly benefi

55 nation, 775 patients underwent veno-arterial extracorporeal membrane oxygenation, and 412 underwent e

56 istent pulmonary hypertension, nitric oxide, extracorporeal membrane oxygenation, and American Colleg

57 Additionally, exchange transfusion, extracorporeal membrane oxygenation, and intubation occu

58 tion cardiac arrest, the use of inotropes on extracorporeal membrane oxygenation, and post-extracorpo

59 een intra-aortic balloon pump, veno-arterial extracorporeal membrane oxygenation, and significant neu

60 al localization of a total artificial heart, extracorporeal membrane oxygenation, and their potential

61 system, the TandemHeart, and venous-arterial extracorporeal membrane oxygenation-and highlight gaps i

62 to analyze the relationship between hospital extracorporeal membrane oxygenation annual volume and in

63 Adolescents treated with neonatal extracorporeal membrane oxygenation are at risk of verba

64 Major complications caused by extracorporeal membrane oxygenation are bleeding, thromb

65 Mechanical circulatory support and extracorporeal membrane oxygenation are increasingly use

66 cquired pneumonia in adults receiving rescue extracorporeal membrane oxygenation are mainly confined

67 Brain-dead patients with ongoing extracorporeal membrane oxygenation are suitable for org

68 emHeart (CardiacAssist, Pittsburgh, PA), and extracorporeal membrane oxygenation, are more accessible

69 al membrane oxygenation support factors, pre-extracorporeal membrane oxygenation arrest (adjusted odd

70 Pediatric centers with low extracorporeal membrane oxygenation average annual case

71 use were associated with mortality, whereas extracorporeal membrane oxygenation before implantation

72 307 minutes after rescue until venoarterial extracorporeal membrane oxygenation blood flow had been

73 embrane oxygenation (2.8 [1.2-6.9]), and pre-extracorporeal membrane oxygenation blood lactate greate

74 Percutaneous cannulation for extracorporeal membrane oxygenation by intensivists can

75 Extracorporeal membrane oxygenation can be used effectiv

76 ed blood stream infections, two colitis, one extracorporeal membrane oxygenation cannula infection, a

77 d for days by the concurrent placement of an extracorporeal membrane oxygenation cannula.

78 l membrane oxygenation flows at 4 hours post-extracorporeal membrane oxygenation cannulation (odds ra

79 Pre-extracorporeal membrane oxygenation cardiac arrest, cont

80 In a multivariable model, age, pre-extracorporeal membrane oxygenation cardiac arrest, the

81 Support Organization from 350 international extracorporeal membrane oxygenation centers during 1992-

82 Three-hundred ninety-four extracorporeal membrane oxygenation centers registered w

83 trategies were routinely used in high-volume extracorporeal membrane oxygenation centers.

84 ate model evaluating adverse events while on extracorporeal membrane oxygenation, central nervous sys

85 adverse outcome were diagnosis, age at start extracorporeal membrane oxygenation, convulsions, and us

86 n injury biomarker concentrations during the extracorporeal membrane oxygenation course are associate

87 We recorded clinical, neuroimaging, and extracorporeal membrane oxygenation course data.

88 State Behavioral Scale scores -3/-2 (34%) by extracorporeal membrane oxygenation day 3.

89 , increased by 36% and 58%, respectively, by extracorporeal membrane oxygenation day 3.

90 Early extracorporeal membrane oxygenation deployment prior to

91 ted blood flow from peripheral veno-arterial extracorporeal membrane oxygenation due to intra-aortic

92 n a cohort of consecutive patients receiving extracorporeal membrane oxygenation during catheter abla

93 n advancements include the increasing use of extracorporeal membrane oxygenation during the periopera

94 ed renewed interest in the use of venovenous extracorporeal membrane oxygenation (ECMO) and extracorp

95 Extracorporeal membrane oxygenation (ECMO) and mechanica

96 ticle, we are describing our experience with extracorporeal membrane oxygenation (ECMO) application.

97 The use of extracorporeal membrane oxygenation (ECMO) for both resp

98 The use of extracorporeal membrane oxygenation (ECMO) for severe ac

99 Extracorporeal membrane oxygenation (ECMO) has long serv

100 Extracorporeal membrane oxygenation (ECMO) is being incr

101 Utilization of extracorporeal membrane oxygenation (ECMO) is expanding

102 The use of extracorporeal membrane oxygenation (ECMO) is growing ra

103 RATIONALE: Extracorporeal membrane oxygenation (ECMO) is used for r

104 High extracorporeal blood flow venovenous extracorporeal membrane oxygenation (ECMO) may therefore

105 Extracorporeal membrane oxygenation (ECMO) provides circ

106 rt Tx (1993-2013) to determine the effect of extracorporeal membrane oxygenation (ECMO) support at th

107 ivariate analysis, the use of posttransplant extracorporeal membrane oxygenation (ECMO) was the stron

108 a weaning strategy using awake venoarterial extracorporeal membrane oxygenation (ECMO).

109 transplantation on ECLS technologies, mainly extracorporeal membrane oxygenation (ECMO).

110 er left ventricular assist devices (LVAD) or extracorporeal membrane oxygenation (ECMO).

111 ear, participants returned for two simulated extracorporeal membrane oxygenation emergencies (Sim2-pu

112 Participants had a preintervention simulated extracorporeal membrane oxygenation emergency (Sim1-reci

113 e regression analysis identified certain pre-extracorporeal membrane oxygenation factors as predictor

114 e logistic regression to explore patient and extracorporeal membrane oxygenation factors associated w

115 pre-extracorporeal membrane oxygenation and extracorporeal membrane oxygenation factors.

116 shorter ventilation time and lesser need of extracorporeal membrane oxygenation, favored conventiona

117 o, 2.4; 95% CI, 1.1-5.0) and need for higher extracorporeal membrane oxygenation flows at 4 hours pos

118 quency ablation is feasible without altering extracorporeal membrane oxygenation flows.

119 There were 150 separate runs of extracorporeal membrane oxygenation for 147 patients wit

120 05 patients were implanted with venoarterial-extracorporeal membrane oxygenation for acute decompensa

121 of 105 patients implanted with venoarterial-extracorporeal membrane oxygenation for acute decompensa

122 tcomes of patients treated with venoarterial-extracorporeal membrane oxygenation for acute decompensa

123 ed five patients implanted with venoarterial-extracorporeal membrane oxygenation for acute decompensa

124 sedation management in children supported on extracorporeal membrane oxygenation for acute respirator

125 lantation recipients treated with venovenous extracorporeal membrane oxygenation for acute respirator

126 ll transplantation do not support the use of extracorporeal membrane oxygenation for acute respirator

127 total of 90% of patients were supported with extracorporeal membrane oxygenation for an average of 5

128 ric ventricular assist device is superior to extracorporeal membrane oxygenation for bridge to heart

129 on for respiratory failure, 2) veno-arterial extracorporeal membrane oxygenation for cardiogenic shoc

130 d data on adult patients (> 18 yr) receiving extracorporeal membrane oxygenation for community-acquir

131 Venovenous extracorporeal membrane oxygenation for patients with se

132 f-life of patients supported by venoarterial extracorporeal membrane oxygenation for refractory cardi

133 Adult patients treated with extracorporeal membrane oxygenation for respiratory fail

134 port cohorts were as follows: 1) veno-venous extracorporeal membrane oxygenation for respiratory fail

135 tely 7% of adults supported with veno-venous extracorporeal membrane oxygenation for respiratory fail

136 uded 4,988 adults supported with veno-venous extracorporeal membrane oxygenation for respiratory fail

137 mortality in patients undergoing veno-venous extracorporeal membrane oxygenation for respiratory fail

138 s (>/= 18 yr old) supported with veno-venous extracorporeal membrane oxygenation for respiratory fail

139 ons in adult patients undergoing veno-venous extracorporeal membrane oxygenation for respiratory fail

140 ntricular dysfunction, received venoarterial extracorporeal membrane oxygenation for septic shock ref

141 ctices in patients supported with venovenous extracorporeal membrane oxygenation for severe acute res

142 essel in adults who have received venovenous extracorporeal membrane oxygenation for severe respirato

143 vein thrombosis following decannulation from extracorporeal membrane oxygenation for severe respirato

144 All primary cases supported with veno-venous extracorporeal membrane oxygenation from 2007 to 2016 (n

145 e consecutive patients who were treated with extracorporeal membrane oxygenation from January 2010 to

146 e higher severity scores at admission in the extracorporeal membrane oxygenation group.

147 mbrane oxygenation and 10,805 donors without extracorporeal membrane oxygenation had at least one org

148 Brain-dead patients with ongoing extracorporeal membrane oxygenation have more severe med

149 Comparative studies with extracorporeal membrane oxygenation have not been comple

150 xtracorporeal membrane oxygenation, and post-extracorporeal membrane oxygenation hypoglycemia were sh

151 During veno-venous extracorporeal membrane oxygenation, hypoxemia (odds rat

152 on therapy (1D), and we suggest venoarterial extracorporeal membrane oxygenation if available (2D).

153 We suggest venoarterial extracorporeal membrane oxygenation, if available, when

154 percutaneous mechanical circulatory support, extracorporeal membrane oxygenation, Impella, and Tandem

155 l exhibited severe myocardial dysfunction at extracorporeal membrane oxygenation implantation.

156 The use of extracorporeal membrane oxygenation in adults with respi

157 ive recommendation for or against the use of extracorporeal membrane oxygenation in patients with sev

158 rtic balloon pump to peripheral venoarterial extracorporeal membrane oxygenation in patients with sev

159 piratory distress syndrome were supported on extracorporeal membrane oxygenation, including 29 manage

160 core for predicting mortality at the time of extracorporeal membrane oxygenation initiation for child

161 atient undergoing noninvasive ventilation at extracorporeal membrane oxygenation initiation had to be

162 alue of urinary output within 24 hours after extracorporeal membrane oxygenation initiation on mortal

163 rporeal membrane oxygenation patients before extracorporeal membrane oxygenation initiation were asso

164 Following venovenous extracorporeal membrane oxygenation initiation, 97% resp

165 ateau pressure greater than 30 cm H2O before extracorporeal membrane oxygenation initiation, and lact

166 lity included time between ICU admission and extracorporeal membrane oxygenation initiation, plateau

167 rwent noninvasive ventilation at the time of extracorporeal membrane oxygenation initiation, were ana

168 h G- (48%) (4 [2-10] vs. 13 [7-23] days from extracorporeal membrane oxygenation initiation; p < 0.00

169 essity of renal replacement therapy prior to extracorporeal membrane oxygenation insertion was an ind

170 requiring renal replacement therapy prior to extracorporeal membrane oxygenation insertion was negati

171 better understanding and management of brain/extracorporeal membrane oxygenation interaction to avoid

172 anticoagulation management as well as brain/extracorporeal membrane oxygenation interaction to reduc

173 hrombosis in the cannulated vessel following extracorporeal membrane oxygenation is 8.1/1,000 cannula

174 Extracorporeal membrane oxygenation is a rescue therapy

175 Extracorporeal membrane oxygenation is a rescue therapy

176 Veno-venous extracorporeal membrane oxygenation is an increasingly u

177 duration of mechanical ventilation prior to extracorporeal membrane oxygenation, lower arterial pres

178 Extracorporeal membrane oxygenation may serve as rescue

179 ements included demographic information, pre-extracorporeal membrane oxygenation mechanical ventilati

180 Extracorporeal membrane oxygenation medical directors an

181 Venoarterial extracorporeal membrane oxygenation might represent a va

182 iochemical variables, inotrope requirements, extracorporeal membrane oxygenation mode, duration, and

183 ntiation of CICR in isolated cells from this extracorporeal membrane oxygenation model and in cells i

184 Type and duration of extracorporeal membrane oxygenation, neurologic complica

185 ients also had higher post-transplant use of extracorporeal membrane oxygenation (odds ratio, 2.35; 9

186 Veno-arterial extracorporeal membrane oxygenation offers the advantage

187 between oxygenation measured 24 hours after extracorporeal membrane oxygenation onset and mortality

188 ine, recipient black race, sex mismatch, and extracorporeal membrane oxygenation or mechanical ventil

189 profiles 1 and 2, the need for preoperative extracorporeal membrane oxygenation or renal replacement

190 eoperative inotropic (OR, 2.61; P=0.001) and extracorporeal membrane oxygenation (OR, 1.68; P=0.05) s

191 xygen of at least 0.30 for at least 4 hours, extracorporeal membrane oxygenation, or mechanical venti

192 technology, and approach used for venovenous extracorporeal membrane oxygenation over the last 10 yea

193 death (18 vs. 8 deaths/1,000 person-days of extracorporeal membrane oxygenation; p = 0.037) and long

194 independent risk factor for poor outcome in extracorporeal membrane oxygenation patients after cardi

195 ence of intracranial hemorrhage was 16.4% in extracorporeal membrane oxygenation patients and 7.6% in

196 predicting hospital mortality in veno-venous extracorporeal membrane oxygenation patients before extr

197 Extracorporeal membrane oxygenation patients experienced

198 Compared to extracorporeal membrane oxygenation patients managed per

199 for Respiratory Failure protocol, usual care extracorporeal membrane oxygenation patients received mo

200 Most extracorporeal membrane oxygenation patients received ne

201 ediction of hospital outcomes in veno-venous extracorporeal membrane oxygenation patients, they do no

202 of a large international cohort of pediatric extracorporeal membrane oxygenation patients.

203 minants of long-term survival in veno-venous extracorporeal membrane oxygenation patients.

204 dence and time course of thrombocytopenia in extracorporeal membrane oxygenation patients.

205 ergent total artificial heart and venovenous extracorporeal membrane oxygenation placement.

206 Pediatric Pulmonary Rescue with Extracorporeal Membrane Oxygenation Prediction is a vali

207 The Pediatric Pulmonary Rescue with Extracorporeal Membrane Oxygenation Prediction score inc

208 xygenation Prediction score included mode of extracorporeal membrane oxygenation; preextracorporeal m

209 Extracorporeal membrane oxygenation provides support for

210 cute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation receiving mechanical

211 ved in these patients with severe ARDS under extracorporeal membrane oxygenation reinforces the need

212 Extracorporeal membrane oxygenation represents a valuabl

213 Venoarterial extracorporeal membrane oxygenation rescued more than 70

214 vivo postarrest myocardial dysfunction using extracorporeal membrane oxygenation resuscitation follow

215 seek to illustrate the impact of veno-venous extracorporeal membrane oxygenation return blood flow up

216 Veno-venous extracorporeal membrane oxygenation return flow generate

217 s to less than 18 years old, with an initial extracorporeal membrane oxygenation run for respiratory

218 e and the University Hospital Regensburg pre-extracorporeal membrane oxygenation score for predicting

219 Only 17% of patients with pre-extracorporeal membrane oxygenation Sequential Organ Fai

220 al was 42%, but better for patients with pre-extracorporeal membrane oxygenation Sequential Organ Fai

221 analyses retained (odds ratio [95% CI]) pre-extracorporeal membrane oxygenation Sequential Organ Fai

222 In patients requiring extracorporeal membrane oxygenation, short- and long-ter

223 Venoarterial-extracorporeal membrane oxygenation should be considered

224 y distress syndrome patients managed without extracorporeal membrane oxygenation support (p < 0.001).

225 ents with renal replacement therapy prior to extracorporeal membrane oxygenation support (p = 0.003).

226 for fewer days (P = 0.03), less often needed extracorporeal membrane oxygenation support (P = 0.007),

227 spiratory distress syndrome under venovenous extracorporeal membrane oxygenation support and to analy

228 plications in adult patients on venoarterial extracorporeal membrane oxygenation support are common a

229 timal mechanical ventilation strategy during extracorporeal membrane oxygenation support are warrante

230 The median extracorporeal membrane oxygenation support duration was

231 pre-extracorporeal membrane oxygenation and extracorporeal membrane oxygenation support factors, pre

232 ortality in patients undergoing venoarterial extracorporeal membrane oxygenation support following ca

233 In children, the initiation of extracorporeal membrane oxygenation support is associate

234 The median time on veno-venous extracorporeal membrane oxygenation support was 13.5 day

235 ecessity of renal replacement therapy during extracorporeal membrane oxygenation support was not an i

236 as acute kidney injury that developed during extracorporeal membrane oxygenation support was not.

237 y pressure levels during the first 3 days of extracorporeal membrane oxygenation support were associa

238 y pressure levels during the first 3 days on extracorporeal membrane oxygenation support were indepen

239 ventilation, intra-aortic balloon pump, and extracorporeal membrane oxygenation support, respectivel

240 ity, hypoxemia, and dependency on venovenous extracorporeal membrane oxygenation support.

241 y to a minimum of 133 G/L by the last day of extracorporeal membrane oxygenation support.

242 on initiation, and lactate level on day 3 of extracorporeal membrane oxygenation support.

243 reated with renal replacement therapy during extracorporeal membrane oxygenation support.

244 and intracranial hemorrhage occurring during extracorporeal membrane oxygenation support.

245 children with respiratory failure receiving extracorporeal membrane oxygenation support.

246 Extracorporeal membrane oxygenation-supported ablation w

247 th community-acquired pneumonia supported on extracorporeal membrane oxygenation survived.

248 lation venous Doppler ultrasound in 88.9% of extracorporeal membrane oxygenation survivors.

249 The three different extracorporeal membrane oxygenation systems did not show

250 study was to compare the impact of different extracorporeal membrane oxygenation systems on blood hem

251 ere randomly assigned to the three different extracorporeal membrane oxygenation systems.

252 Three different extracorporeal membrane oxygenation systems: the Cardioh

253 For patients supported with veno-venous extracorporeal membrane oxygenation, the occurrence of i

254 ally ventilator-associated pneumonia) during extracorporeal membrane oxygenation therapy are common a

255 redictor of mortality in patients undergoing extracorporeal membrane oxygenation therapy following ca

256 U management may be potential candidates for extracorporeal membrane oxygenation therapy in case of s

257 Over time, miniaturized veno-venous extracorporeal membrane oxygenation therapy increasingly

258 elet count had dropped from 220.5 G/L before extracorporeal membrane oxygenation therapy to a minimum

259 We recommend early initiation of extracorporeal membrane oxygenation therapy to mitigate

260 During the first 5 days of extracorporeal membrane oxygenation therapy, prothrombin

261 matory parameters within the first 5 days of extracorporeal membrane oxygenation therapy.

262 lood hemostasis in adults during veno-venous extracorporeal membrane oxygenation therapy.

263 In patients who received veno-venous extracorporeal membrane oxygenation, there was no signif

264 rs (63%); 41% respondents provide venovenous extracorporeal membrane oxygenation to adults exclusivel

265 vice critical care fellows, simulation-based extracorporeal membrane oxygenation training is superior

266 We compared traditional water-drill-based extracorporeal membrane oxygenation training with simula

267 e oxygenation training with simulation-based extracorporeal membrane oxygenation training with the hy

268 Although good outcomes of venoarterial extracorporeal membrane oxygenation-treated children wit

269 Extracorporeal membrane oxygenation treatment in adult p

270 Extracorporeal membrane oxygenation treatment or extraco

271 patients who survive the first months after extracorporeal membrane oxygenation treatment, long-term

272 acorporeal membrane oxygenation treatment or extracorporeal membrane oxygenation type did not influen

273 rimary outcome was a composite of mortality, extracorporeal membrane oxygenation use, and need for su

274 in-derived neurotrophic factor) daily during extracorporeal membrane oxygenation, using an electroche

275 Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increas

276 pre-extracorporeal membrane oxygenation and extracorporeal membrane oxygenation variables associated

277 (p = 0.91): 86.5% (70.5-94.1) from donors on extracorporeal membrane oxygenation versus 80.7% (79.8-8

278 Although extracorporeal membrane oxygenation volume has increased

279 Average hospital extracorporeal membrane oxygenation volume ranged from 1

280 Extracorporeal membrane oxygenation was applied within 4

281 Extracorporeal membrane oxygenation was deployed during

282 Extracorporeal membrane oxygenation was identified an im

283 em database from 2004 to 2011 supported with extracorporeal membrane oxygenation was identified.

284 From 2010 to 2015, extracorporeal membrane oxygenation was initiated in 64

285 p was inserted, and peripheral veno-arterial extracorporeal membrane oxygenation was initiated with s

286 ) (odds ratio, 0.73 [0.57-0.91]; p = 0.009); extracorporeal membrane oxygenation was not an independe

287 Extracorporeal membrane oxygenation was used as a rescue

288 Venoarterial extracorporeal membrane oxygenation was used for cardiac

289 r research, this was the first case in which extracorporeal membrane oxygenation was used to treat se

290 presence of more than three complications on extracorporeal membrane oxygenation were also associated

291 lower delivered tidal volume after 3 days on extracorporeal membrane oxygenation were associated with

292 emofiltration, and hyperbilirubinemia during extracorporeal membrane oxygenation were associated with

293 Donors on extracorporeal membrane oxygenation were significantly y

294 significantly lower plateau pressures during extracorporeal membrane oxygenation were used in the Fre

295 n oxygenation and mortality in veno-arterial extracorporeal membrane oxygenation which may be due to

296 n of unstable VTs can be safely supported by extracorporeal membrane oxygenation, which allows rhythm

297 on was successful in 9 patients on full flow extracorporeal membrane oxygenation with 3 radiofrequenc

298 We identified 103 patients commenced on extracorporeal membrane oxygenation with 81 survivors fr

299 ntra-aortic balloon pump and/or venoarterial extracorporeal membrane oxygenation with neurologic inju

300 Only one of 24 patients (4%) initiated on extracorporeal membrane oxygenation within 240 days afte